Quest Diagnostics Completes Sale of India Diagnostics Services Business to Strand Life Sciences

December 21, 2018

SECAUCUS, N.J., Dec. 21, 2018 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has completed the sale of its India medical diagnostic service business to Strand Life Sciences, a Bangalore-based specialized diagnostics company.

Terms of this transaction were not disclosed. Alvarez & Marsal Corporate Finance & Restructuring, India acted as the exclusive financial advisor to Quest Diagnostics.

About Quest Diagnostics

Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.

About Strand Life Sciences

Strand Life Sciences is a clinical research and diagnostics company that combines a long track record in bioinformatics with cutting-edge laboratory assays and a vast hospital partner network to drive newer generations of patient care. Strand's customers include global instrument, diagnostic and pharmaceutical companies. Strand is also a pioneer of genomic testing in India. Strand's diagnostics menu makes it India's leading integrated specialized diagnostics company, covering oncology, genetics, fertility, women's health, infectious diseases and general wellness. For more information, visit Strand's website at www.strandis.com/

SOURCE Quest Diagnostics

Rachel Carr, 973-520-2800